ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1058

Resolution of Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis While Maintaining Active Treatment with Checkpoint Inhibitors

Alexandra Ladouceur1, Thomas Barnetche2, Sorilla Mary-Prey3, Caroline Dutriaux4, Emilie Gerard3, Anne Pham-Ledard3, Marie Beylot-Barry3, Maeva Zysman3, Rémi Veillon3, Charlotte Domblides5, Amaury Daste5, Marine Gross-Goupil5, Baptiste Sionneau5, Félix Lefort5, Mathieu Larroquette5, Christophe Richez6, Marie-Elise Truchetet2, Thierry Schaeverbebke7 and Marie Kostine2, 1Department of Rheumatology of McGill University and CHU-Bordeaux, Montréal, QC, Canada, 2Bordeaux University Hospital, Bordeaux, France, 3Department of Dermatology, Bordeaux University Hospital, Bordeaux, France, 4CHU-Bordeaux, Bordeaux, France, 5Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France, 6Université de Bordeaux, Bordeaux, France, 7University Hospital of Bordeaux, Bordeaux, France

Meeting: ACR Convergence 2023

Keywords: Drug toxicity, Oncology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 13, 2023

Title: (1052–1081) Immunological Complications of Medical Therapy Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Immune checkpoint inhibitors (ICI) are a revolutionary treatment that boost a patient’s own immune system to fight cancer. However, activation of the immune system often induces off-target immune-related adverse events (irAEs). ICI-induced inflammatory arthritis (ICI-IA) affects about 5% of ICI recipients and can lead to ICI discontinuation which might potentially negatively affect tumor outcomes. We aimed 1) to characterize the evolution of ICI-IA while ICI treatment is maintained and 2) to assess how ICI-IA influences ICI management across time.

Methods: All ICI-treated patients referred to rheumatology at Bordeaux University Hospital were identified and patients with ICI-IA defined by either the presence of at least one synovitis on physical exam and/or on imaging or polymyalgia rheumatica (PMR)-like symptoms with a follow-up of ≥ 6 months after ICI-IA onset were included. Charts were manually reviewed to extract data on baseline characteristics, investigations, management and both ICI-IA and tumor outcomes.

Results: Out of 281 referred patients, 80 fulfilled the inclusion criteria, of which 49 (61.3%) were male. The median duration follow-up after ICI-IA onset was 108 weeks [ranging from 26-330 weeks]. The most common tumor was melanoma (n=38, 47.5%), followed by lung cancer (n=16, 20.0%). The mean time from ICI-IA onset to ICI-IA treatment was 8.6 weeks and ICI was continued in 63 patients (78.8%) or temporary held in 11 (13.8%). Prednisone was prescribed in 74 patients (92.5%), csDMARDs in 22 (27.5%) and biologics in 2 (2.5%). ICI-IA resolved allowing ICI-IA treatment discontinuation in 27 patients (33.8%) while still being treated with ICI. Among those, 26 (96.3%) were treated with prednisone (median maximal dose 15 mg and median duration 52.0 weeks), 3 (11.1%) with csDMARDs and 1 (3.7%) with biologics. In patients with persistent ICI-IA while on ICI, 20 (40%) and 34 (68%) had resolved at 6 and 12 months post ICI discontinuation, respectively. During follow-up, the main reason for ICI discontinuation was a cancer stable or in remission in 31 patients (38.8%), cancer progression in 22 (27.5%), other irAE in 7 (8.8%) and ICI-IA in 4 (5.0%). Of note, ICI-IA treatment and ICI management were similar between those with active arthritis and those with resolved arthritis at 6 and 12 months post ICI discontinuation.

Conclusion: In this cohort, ICI was safely continued in most patients experiencing ICI-IA. Over one third of ICI-IA resolved despite maintaining active ICI treatment allowing arthritis treatment discontinuation. Larger studies are needed to determine predicting factors of resolving ICI-IA as this could help minimize exposure to immunosuppressive treatment.


Disclosures: A. Ladouceur: None; T. Barnetche: Eli Lilly, 2; S. Mary-Prey: Bristol-Myers Squibb(BMS), 2, 12, Congress fees participation, Merck/MSD, 2, 12, Congress fees reimbursement; C. Dutriaux: Bristol-Myers Squibb(BMS), 1, 2, 12, Clinical trials, travel and accomodation fees, Merck/MSD, 2, 12, Clinical trials, travel and accomodation fees for boards or congress, Novartis, 2, 12, Clinical trials, travel and accomodation fees; E. Gerard: Bristol-Myers Squibb(BMS), 1, 12, Clinical trials, travel to scientific meetings, Merck/MSD, 1, 12, Clinical trials, travel to scientific meetings; A. Pham-Ledard: Bristol-Myers Squibb(BMS), 12, conference participation fees, Merck/MSD, 12, Congress participation fees; M. Beylot-Barry: None; M. Zysman: AstraZeneca, 2, Bristol-Myers Squibb(BMS), 2; R. Veillon: AbbVie/Abbott, 5, Amgen, 6, AstraZeneca, 6, 12, Travel, accomodations, expenses, Bristol-Myers Squibb(BMS), 5, 5, 6, GlaxoSmithKlein(GSK), 5, Janssen, 2, Merck/MSD, 5, Novartis, 5, Roche, 6; C. Domblides: Amgen, 4, 12, travel/congress, AstraZeneca, 1, 12, travel/congress, Bristol-Myers Squibb(BMS), 1, 12, Travel/congress, Janssen, 1, Merck/MSD, 4, 12, Travel/congress, Pfizer, 12, Travel/congress, Roche, 12, Travel/congress; A. Daste: Bristol-Myers Squibb(BMS), 2, Merck/MSD, 2; M. Gross-Goupil: Amgen, 6, Bristol-Myers Squibb(BMS), 1, 6, 12, Clinical research, Merck/MSD, 1, 6, 12, Clinical research, Pfizer, 1, 12, Clinical research, Roche, 12, Clinical research; B. Sionneau: None; F. Lefort: AstraZeneca, 1, 2, 12, Clinical trials, Bristol-Myers Squibb(BMS), 12, Clinical trials, Merck/MSD, 1, 2, 12, Clinical trials, Pfizer, 12, Travel and accomodation fees, Roche, 12, Clinical trials; M. Larroquette: None; C. Richez: AbbVie/Abbott, 2, 6, Amgen, 6, AstraZeneca, 2, 6, Bristol-Myers Squibb(BMS), 6, Eli Lilly, 6, 12, receipt of drugs, GlaxoSmithKlein(GSK), 2, 6, Novartis, 2, 6, Pfizer, 2, 6; M. Truchetet: AbbVie/Abbott, 2, 6, Boehringer-Ingelheim, 2, 6, Gilead, 5, 6, Merck/MSD, 6, UCB, 6, 12, support for conferences; T. Schaeverbebke: AbbVie/Abbott, 1, 6, 12, Clinical trials, Bristol-Myers Squibb(BMS), 1, 1, 6, 6, Eli Lilly, 1, 5, 6, 12, Clinical trials, Janssen, 6, Merck/MSD, 12, Clinical trials, Novartis, 1, 6, 12, Clinical trials, Pfizer, 1, 5, 12, Clinical trials; M. Kostine: None.

To cite this abstract in AMA style:

Ladouceur A, Barnetche T, Mary-Prey S, Dutriaux C, Gerard E, Pham-Ledard A, Beylot-Barry M, Zysman M, Veillon R, Domblides C, Daste A, Gross-Goupil M, Sionneau B, Lefort F, Larroquette M, Richez C, Truchetet M, Schaeverbebke T, Kostine M. Resolution of Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis While Maintaining Active Treatment with Checkpoint Inhibitors [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/resolution-of-immune-checkpoint-inhibitors-induced-inflammatory-arthritis-while-maintaining-active-treatment-with-checkpoint-inhibitors/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/resolution-of-immune-checkpoint-inhibitors-induced-inflammatory-arthritis-while-maintaining-active-treatment-with-checkpoint-inhibitors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology